At Urology of Virginia, research studies form a vital component of our mission. These studies, referred to as clinical trials, are designed by physicians and researchers to investigate new medical therapies. Well-designed clinical trials offer the newest, most promising drugs and treatments for urological conditions to our community.
Our staff’s experienced investigators and certified clinical research coordinators closely monitor participating patients during the course of a study period. All clinical trials are conducted according to the principles of Good Clinical Practice (GCPs) as mandated by the FDA.
- Participants have access to advanced medications or devices before they become available to the public.
- Clinical study procedures may be provided to you at no cost.
- Participants often express enthusiasm for contributing to medical science.
- Today’s clinical research can positively impact future generations.
Enrolling Clinical Studies at Urology of Virginia
This Phase III study is designed for patients that are “BCG Unresponsive” which refers to patients with high grade non-muscle invasive bladder cancer (NMIBC) who are unlikely to benefit from and should not receive further intravesical BCG.
Get detailed information about this clinical trial»
Merck MK-3475-057: “Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer”
In this study, participants with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG) therapy and who are considered ineligible for or have refused to undergo radical cystectomy, will receive pembrolizumab therapy.
Get detailed information about this clinical trial»
TARIS: “Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy”
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles.
Get detailed information about this clinical trial»
Urogen Pharma: “The OLYMPUS Study – Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)”
The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles.
Expected Management
Canary PASS: a multicenter, prospective active surveillance study with selective intervention in patients with previously untreated, clinically localized prostate cancer at diagnosis. The objective is to discover and confirm biomarkers that predict aggressive disease.
Hormone Therapy (ADT)
Foresee LMIS: “Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate CancerSubjects with Prostate Cancer”
The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with prostate cancer, when administered as two injections twelve weeks apart.Study designed for men who require at least 6 months of hormone therapy (ADT).
Get detailed information about this clinical trial»
Ferring PRONOUNCE: “A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease”
Purpose of this trial is to test if a marketed drug for advanced prostate cancer (FIRMAGON) can reduce the risk of cardiovascular complications as compared to another marketed drug for advanced prostate cancer (LUPRON DEPOT) in patients with prostate cancer and cardiovascular disease. Qualified patients for this study will receive either Firmagon® or Lupron®.
Get detailed information about this clinical trial»
Myovant HERO: “A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer”
The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression in patients with androgen-sensitive advanced prostate cancer. Study participants will be randomized 2:1 to oral relugolix once daily or leuprolide acetate 3-month depot intramuscular injection and will attend visits monthly.
Get detailed information about this clinical trial»
Non-metastatic: Cancer that has not spread to other areas
Pfizer EMBARK: “Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer”
The purpose of this study is to assess enzalutamide plus leuprolide in patients with high-risk nonmetastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both.
Get detailed information about this clinical trial»
Janssen ATLAS: “An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy”
The purpose of this study is to determine if apalutamide plus androgen deprivation therapy (ADT) in participants with high-risk, localized or locally advanced prostate cancer receiving primary radiation therapy results in an improvement of metastasis-free survival.
Get detailed information about this clinical trial»
Metastatic disease: Cancer that has spread to other areas
Clovis TRITON3: “A Study of Rucaparib Versus Physician’s Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency”
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician’s choice of abiraterone acetate, enzalutamide, or docetaxel. Patients will be screened for the deleterious mutation in a BRCA1/2 or ATM gene to qualify.
Stone Disease
Allena ALLN-177: “Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria”
The purpose of this study is to determine the efficacy and safety of ALLN-177 in patients with enteric hyperoxaluria.
Get detailed information about this clinical trial»
Incontinence
Ipsen CONTENT1 “Dysport® for urinary incontinence due to multiple sclerosis (MS) or spinal cord injury (SCI)”
The purpose of this study is to provide confirmatory evidence of the safety and efficacy of two Dysport® (AbobotulinumtoxinA) doses (600 units [U] and 800 U), compared to placebo in reducing urinary incontinence (UI) in adult subjects treated for neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS).
Get detailed information about this clinical trial»
Allergan APOLLO: “BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence”
This study will evaluate the efficacy and safety of BOTOX® intravesical instillation in participants with overactive bladder and urinary incontinence.
Get detailed information about this clinical trial»
TARIS: “Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury”
The purpose of this study is to determine if an investigational Trospium-Releasing Intravesical System (TAR-302-5018), is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).
Get detailed information about this clinical trial»
Urovant EMPOWUR: “Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder”
Vibegron is an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Get detailed information about this clinical trial»
Urethral Stricture
Urotronic ROBUST-II: “Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease”
The study is designed to assess the safety and device performance for the drug coated balloon (DCB) for the treatment of urethral stricture.
Get detailed information about this clinical trial»
Interstitial Cystitis/Bladder Pain Syndrome
Urigen ENGAGE24: “Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome”
The purpose of this study is to determine if the combination product (URG101) is safe and effective versus its individual components (Heparin Sodium and Lidocaine Hydrochloride) for the treatment of Interstitial Cystitis/Bladder Pain Syndrome.
Get detailed information about this clinical trial»
Pelvic Organ Prolapse
No Enrolling Studies at This Time
Hypogonadism
No Enrolling Studies at This Time
Nocturia
No Enrolling Studies at This Time
BPH (Enlarged Prostate)
No Enrolling Studies at This Time